Inflammation

Portfolio PipelineBeyond our oncology and CNS therapeutic focus, we also have one programme in inflammation, partnered with Verona Pharma 

 

Inflammatory disease

Persistent and poorly treated

A whole spectrum of inflammatory diseases may affect the human body. Some of these conditions are well understood and well-treated, but many are not. Unmet medical need and significant market potential mean that this is another priority pipeline asset we are determined to exploit to the full.

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch